PT980252E - Terapias para insuficiencia renal aguda - Google Patents

Terapias para insuficiencia renal aguda

Info

Publication number
PT980252E
PT980252E PT98919715T PT98919715T PT980252E PT 980252 E PT980252 E PT 980252E PT 98919715 T PT98919715 T PT 98919715T PT 98919715 T PT98919715 T PT 98919715T PT 980252 E PT980252 E PT 980252E
Authority
PT
Portugal
Prior art keywords
acute renal
therapies
renal insufficiency
risk
treatment
Prior art date
Application number
PT98919715T
Other languages
English (en)
Inventor
Charles M Cohen
Kuber T Sampath
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of PT980252E publication Critical patent/PT980252E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT98919715T 1997-05-05 1998-05-05 Terapias para insuficiencia renal aguda PT980252E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
PT980252E true PT980252E (pt) 2005-01-31

Family

ID=21938961

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98919715T PT980252E (pt) 1997-05-05 1998-05-05 Terapias para insuficiencia renal aguda

Country Status (11)

Country Link
US (2) US20100105621A1 (pt)
EP (1) EP0980252B1 (pt)
JP (2) JP5033276B2 (pt)
AT (1) ATE278414T1 (pt)
AU (1) AU743510B2 (pt)
CA (1) CA2289123A1 (pt)
DE (1) DE69826854T2 (pt)
DK (1) DK0980252T3 (pt)
ES (1) ES2226125T3 (pt)
PT (1) PT980252E (pt)
WO (1) WO1998050060A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481111T1 (de) * 2000-01-31 2010-10-15 Rothenpieler Uwe Waldemar Pax2 zur behandlung von nierenkrankheiten
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
CA2452114C (en) * 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Tgf-.beta. superfamily production/secretion promoter
WO2004019876A2 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
JP2009515529A (ja) * 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
EP2574625B1 (en) * 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
EP3103466A4 (en) 2014-02-07 2017-11-22 Toru Miyazaki Preventive or therapeutic agent for kidney disease
FR3071065B1 (fr) 2017-09-08 2020-10-02 Dcns Dispositif de controle d'isolement et/ou de continuite d'au moins un cable electrique et procede de controle associe

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
EP0429570B1 (en) 1989-03-28 1998-01-14 Genetics Institute, Inc. Osteoinductive compositions
DK0536186T3 (da) 1990-05-16 2002-05-21 Genetics Inst Knogle- og brusk-dannelsesfremkaldende proteiner
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
EP0533840B1 (en) 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
DE69231946T2 (de) 1991-03-11 2002-04-04 Curis, Inc. Protein-induzierende morphogenese
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0825442A3 (en) 1991-08-30 2004-02-11 Curis, Inc. Morphogenic protein screening method
CA2116562C (en) * 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
DE69233559T2 (de) * 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
AU678380B2 (en) 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof
DE69318166T2 (de) 1992-07-31 1998-10-08 Creative Biomolecules, Inc., Hopkinton, Mass. Mit morphogen angereicherte nahrungszusammenstellung
WO1994006449A2 (en) 1992-09-16 1994-03-31 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
CA2147598A1 (en) 1992-11-03 1994-05-11 Hermann Oppermann Op-3-induced morphogenesis
CA2157387C (en) 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
CA2249596C (en) * 1996-03-22 2011-11-08 Creative Biomolecules, Inc. Methods for enhancing functional recovery following central nervous system ischemia or trauma
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
JP5033276B2 (ja) 2012-09-26
CA2289123A1 (en) 1998-11-12
AU743510B2 (en) 2002-01-24
ES2226125T3 (es) 2005-03-16
JP2001523264A (ja) 2001-11-20
US20100105621A1 (en) 2010-04-29
AU7244398A (en) 1998-11-27
DE69826854T2 (de) 2006-02-02
EP0980252B1 (en) 2004-10-06
WO1998050060A1 (en) 1998-11-12
JP2009286802A (ja) 2009-12-10
ATE278414T1 (de) 2004-10-15
DE69826854D1 (de) 2004-11-11
US20110257093A1 (en) 2011-10-20
US8748378B2 (en) 2014-06-10
DK0980252T3 (da) 2005-01-31
EP0980252A1 (en) 2000-02-23

Similar Documents

Publication Publication Date Title
PT910400E (pt) Terapias para insuficiencia renal cronica
PT980252E (pt) Terapias para insuficiencia renal aguda
Zeisberg et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models
Conway et al. BMP-7 versus BMP-2 for the treatment of long bone nonunion
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
DK0564502T3 (da) Vævsforseglingsmiddel og vækstfaktorholdige præparater, der fremmer accelereret sårheling
NO982436D0 (no) Apparat for oppvarming av blod
NO20001754D0 (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE69729639D1 (de) System für die gefässrekanalisation von stenotischen bypasstransplantaten und sonstigen blutgefässen
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
Xu et al. A novel injectable fibromodulin‐releasing granular hydrogel for tendon healing and functional recovery
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ES2180514T3 (es) Uso de un factor con actividad inhibidora del melanoma (mia) para reparacion de cartilagos y huesos.
Hsieh et al. Porcine platelet lysate intra-articular knee joint injections for the treatment of rabbit cartilage lesions and osteoarthritis
Liang et al. Clinical outcomes of autologous platelet-rich plasma and bone marrow mononuclear cells grafting combined with core decompression for Association Research Circulation Osseous II–IIIA stage non-traumatic osteonecrosis of the femoral head
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
FI952170A0 (fi) Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
Leite et al. ICRS virtual convention 2021: Orthoregenerative therapy from basic science to clinical application
PT1214091E (pt) Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina